RT Journal Article
T1 Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain.
A1 Rivero-Juarez, A
A1 Gutierrez-Valencia, A
A1 Castaño, M
A1 Merino, D
A1 Neukam, K
A1 Ríos-Villegas, M J
A1 Lopez-Ruz, M A
A1 Jiménez-Aguilar, P
A1 Marquez, M
A1 Collado, A
A1 Gomez-Vidal, A
A1 Hernandez-Quero, J
A1 Tellez, F
A1 Fernandez-Fuertes, E
A1 Rivero, A
A1 López-Cortés, L F
K1 Hepacivirus
K1 Hepatopatías
K1 Hepatitis C
K1 VIH
K1 Fallo Hepático
AB The implementation of hepatitis C (HCV) direct-acting antiviral drugs is prioritized in several populations in which its application provides the most immediate and impactful benefit. In this scenario, a precise knowledge of the situation of human immunodeficiency virus (HIV)/HCV chronic co-infection is required to adequately address this disease. This cross-sectional study was performed in 21 hospitals in Andalusia (Spain). The study population consisted of HIV-infected patients with an active HCV chronic infection who were not receiving HCV treatment at the time of inclusion. A total of 13,506 HIV-infected patients were included in the study. Of them, 2561 (18.9 %) presented chronic HCV infection. The majority of the patients included were on highly active antiretroviral therapy (HAART; 96.2 %), showed plasma levels with an undetectable HIV viral load (92.5 %), and had a good immunological status (median CD4+ cell count of 486 cells/mL). The HCV genotype distribution was as follows: 58.1 % were genotype 1, 1.1 % were genotype 2, 16.1 % were genotype 3, and 22.1 % were genotype 4 (2.6 % were missing data). In total, 24.8 % of the patients showed liver fibrosis stage F0-F1, 27.9 % showed stage F2, 16.7 % showed stage F3, and 21 % showed stage F4 (9.6 % were missing data). With regards to previous HCV treatment experiences, 68.05 % of the patients were naïve and 31.95 % had failed to respond to a previous treatment. The burden of HCV/HIV co-infected patients in our population was reported as one in five HIV-infected patients requiring HCV treatment. The implementation of extra resources to face this important health challenge is mandatory.
PB Springer
YR 2015
FD 2015-09-05
LK http://hdl.handle.net/10668/2347
UL http://hdl.handle.net/10668/2347
LA en
NO Rivero-Juarez A, Gutierrez-Valencia A, Castaño M, Merino D, Neukam K, Ríos-Villegas MJ, et al. Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain. Eur J Clin Microbiol Infect Dis. 2015; 34(11):2247-55
NO Journal Article;
DS RISalud
RD Apr 4, 2025